
## Inmaculada Hernandez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2451156/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Risk of Bleeding With Dabigatran in Atrial Fibrillation. JAMA Internal Medicine, 2015, 175, 18.	5.1	249
2	Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018. JAMA - Journal of the American Medical Association, 2020, 323, 854.	7.4	124
3	Exposure-Response Association Between Concurrent Opioid and Benzodiazepine Use and Risk of Opioid-Related Overdose in Medicare Part D Beneficiaries. JAMA Network Open, 2018, 1, e180919.	5.9	115
4	Evaluation of Frequency of Encounters With Primary Care Physicians vs Visits to Community Pharmacies Among Medicare Beneficiaries. JAMA Network Open, 2020, 3, e209132.	5.9	106
5	Total Costs of Chimeric Antigen Receptor T <i>-</i> Cell Immunotherapy. JAMA Oncology, 2018, 4, 994.	7.1	93
6	Access to community pharmacies: A nationwide geographic information systems cross-sectional analysis. Journal of the American Pharmacists Association: JAPhA, 2022, 62, 1816-1822.e2.	1.5	82
7	Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation. American Journal of Cardiology, 2017, 120, 1813-1819.	1.6	80
8	Impact of community pharmacist-led interventions in chronic disease management on clinical, utilization, and economic outcomes: An umbrella review. Research in Social and Administrative Pharmacy, 2020, 16, 1155-1165.	3.0	67
9	Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program. JAMA Network Open, 2020, 3, e2020969.	5.9	66
10	Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data. American Journal of Cardiovascular Drugs, 2017, 17, 37-47.	2.2	51
11	Impact of community pharmacist-provided preventive services on clinical, utilization, and economic outcomes: An umbrella review. Preventive Medicine, 2018, 115, 145-155.	3.4	49
12	Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction. JAMA Network Open, 2021, 4, e2114501.	5.9	49
13	Trajectories of Oral Anticoagulation Adherence Among Medicare Beneficiaries Newly Diagnosed With Atrial Fibrillation. Journal of the American Heart Association, 2019, 8, e011427.	3.7	48
14	Pricing of monoclonal antibody therapies: higher if used for cancer?. American Journal of Managed Care, 2018, 24, 109-112.	1.1	45
15	Anticoagulation Use and Clinical Outcomes After Major Bleeding on Dabigatran or Warfarin in Atrial Fibrillation. Stroke, 2017, 48, 159-166.	2.0	42
16	The Contribution Of New Product Entry Versus Existing Product Inflation In The Rising Costs Of Drugs. Health Affairs, 2019, 38, 76-83.	5.2	42
17	Using predictive analytics and big data to optimize pharmaceutical outcomes. American Journal of Health-System Pharmacy, 2017, 74, 1494-1500.	1.0	40
18	Race/Ethnicity and Sex-Related Differences in Direct Oral Anticoagulant Initiation in Newly Diagnosed Atrial Fibrillation: A Retrospective Study of Medicare Data. Journal of the National Medical Association, 2020, 112, 103-108.	0.8	34

Inmaculada Hernandez

#	Article	IF	CITATIONS
19	Trends in List Prices, Net Prices, and Discounts for Originator Biologics Facing Biosimilar Competition. JAMA Network Open, 2019, 2, e1917379.	5.9	31
20	Trends in Prices, Market Share, and Spending on Self-administered Disease-Modifying Therapies for Multiple Sclerosis in Medicare Part D. JAMA Neurology, 2019, 76, 1386.	9.0	29
21	Evaluating the Initiation of Novel Oral Anticoagulants in Medicare Beneficiaries. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 281-292.	0.9	28
22	Optimizing the Role of Community Pharmacists in Managing the Health of Populations: Barriers, Facilitators, and Policy Recommendations. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 995-1000.	0.9	26
23	Trends in Medicaid Prices, Market Share, and Spending on Long-Acting Insulins, 2006-2018. JAMA - Journal of the American Medical Association, 2019, 321, 1627.	7.4	25
24	Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function. Thrombosis Research, 2017, 150, 123-130.	1.7	22
25	Latent Classes of Adherence to Oral Anticoagulation Therapy Among Patients With a New Diagnosis of Atrial Fibrillation. JAMA Network Open, 2020, 3, e1921357.	5.9	21
26	Adherence to Anticoagulation and Risk of Stroke Among Medicare Beneficiaries Newly Diagnosed with Atrial Fibrillation. American Journal of Cardiovascular Drugs, 2020, 20, 199-207.	2.2	19
27	Impact of Healthcare Delivery System Type on Clinical, Utilization, and Cost Outcomes of Patient-Centered Medical Homes: a Systematic Review. Journal of General Internal Medicine, 2020, 35, 1276-1284.	2.6	19
28	Comparing the Approval and Coverage Decisions of New Oncology Drugs in the United States and Other Selected Countries. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 247-254.	0.9	18
29	Varenicline and Nicotine Replacement Use Associated With US Food and Drug Administration Drug Safety Communications. JAMA Network Open, 2019, 2, e1910626.	5.9	18
30	Geographic Variation in the Use of Oral Anticoagulation Therapy in Stroke Prevention in Atrial Fibrillation. Stroke, 2017, 48, 2289-2291.	2.0	17
31	Cardiac resynchronization therapy using pacemakers vs defibrillators in patients with nonischemic cardiomyopathy: The United States experience from 2007 to 2014. Heart Rhythm, 2019, 16, 1065-1071.	0.7	17
32	Changes in Drug Pricing After Drug Shortages in the United States. Annals of Internal Medicine, 2019, 170, 74.	3.9	16
33	Risk of Bleeding With Dabigatran in 2010-2011 Medicare Data. JAMA Internal Medicine, 2015, 175, 1245.	5.1	14
34	A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections. Expert Opinion on Pharmacotherapy, 2018, 19, 319-325.	1.8	14
35	Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients With Atrial Fibrillation. American Journal of Cardiology, 2018, 122, 69-75.	1.6	12
36	Impact of Star Rating Medication Adherence Measures on Adherence for Targeted and Nontargeted Medications. Value in Health, 2019, 22, 1266-1274.	0.3	12

#	Article	IF	CITATIONS
37	The Skyrocketing Cost of Rectal Indomethacin. JAMA Internal Medicine, 2020, 180, 631.	5.1	12
38	Marked Increase in Sales of Erectile Dysfunction Medication During COVID-19. Journal of General Internal Medicine, 2021, 36, 2912-2914.	2.6	12
39	Drug Shortages in the United States. JAMA - Journal of the American Medical Association, 2020, 323, 819.	7.4	11
40	Non-persistence to Oral Anticoagulation Treatment in Patients with Non-valvular Atrial Fibrillation in the USA. American Journal of Cardiovascular Drugs, 2022, 22, 333-343.	2.2	11
41	The global impact of COVID-19 on drug purchases: A cross-sectional time series analysis. Journal of the American Pharmacists Association: JAPhA, 2022, 62, 766-774.e6.	1.5	11
42	Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy—Reply. JAMA Oncology, 2018, 4, 1785.	7.1	10
43	Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding. American Journal of Cardiovascular Drugs, 2018, 18, 317-325.	2.2	10
44	Assessment of Price Changes of Existing Tumor Necrosis Factor Inhibitors After the Market Entry of Competitors. JAMA Internal Medicine, 2019, 179, 713.	5.1	10
45	Effectiveness and Safety of Restarting Oral Anticoagulation in Patients with Atrial Fibrillation after an Intracranial Hemorrhage: Analysis of Medicare Part D Claims Data from 2010–2016. American Journal of Cardiovascular Drugs, 2020, 20, 471-479.	2.2	9
46	Time to Reconsider Dabigatran 110Âmg in the USA. American Journal of Cardiovascular Drugs, 2015, 15, 307-309.	2.2	8
47	Using machine learning to identify diabetes patients with canagliflozin prescriptions at highâ€risk of lower extremity amputation using realâ€world data. Pharmacoepidemiology and Drug Safety, 2021, 30, 644-651.	1.9	8
48	Risk factors for cardiovascular events of antidementia drugs in Alzheimer's disease patients. Journal of Clinical Gerontology and Geriatrics, 2016, 7, 77-82.	0.7	7
49	Teaching About the Health Care Industry Through Gamification. American Journal of Pharmaceutical Education, 2018, 82, 6422.	2.1	7
50	Association of Antidementia Therapies With Time to Skilled Nursing Facility Admission and Cardiovascular Events Among Elderly Adults With Alzheimer Disease. JAMA Network Open, 2019, 2, e190213.	5.9	7
51	Real-World Direct Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Medicare Beneficiaries With Atrial Fibrillation. American Journal of Cardiology, 2020, 126, 29-36.	1.6	7
52	Revisiting Outcomes–Based Pricing Propositions for the PCSK9 Inhibitor Evolocumab. JAMA Internal Medicine, 2017, 177, 1388.	5.1	6
53	Differences Between Managed Care and Fee-for-Service Medicaid in the Use of Generics for High-Rebate Drugs: The Cases of Insulin Glargine and Glatiramer. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 154-159.	0.9	6
54	Comparing Adoption of Breakthrough and "Me-too―Drugs Among Medicare Beneficiaries: a Case Study of Dipeptidyl Peptidase-4 Inhibitors. Journal of Pharmaceutical Innovation, 2017, 12, 105-109.	2.4	5

#	Article	IF	CITATIONS
55	Interpreting COVID-19 Test Results: a Bayesian Approach. Journal of General Internal Medicine, 2020, 35, 2490-2491.	2.6	5
56	Are novel glucoseâ€lowering agents' cardiorenal benefits generalizable to individuals of <scp>Black</scp> race? A metaâ€trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrolment. Diabetes, Obesity and Metabolism, 2022, 24, 154-159.	4.4	5
57	Effect of the COVID-19 pandemic on adversity in individuals receiving anticoagulation for atrial fibrillation: A nationally representative administrative health claims analysis. American Heart Journal Plus, 2022, 13, 100096.	0.6	5
58	COVIDâ€19 and Anticoagulation for Atrial Fibrillation: An Analysis of US Nationwide Pharmacy Claims Data. Journal of the American Heart Association, 2021, 10, e023235.	3.7	5
59	Comparing clinical and economic outcomes of biologic and conventional medications in postmenopausal women with osteoporosis. Journal of Evaluation in Clinical Practice, 2015, 21, 840-847.	1.8	4
60	Pharmaceutical Use and Spending Trend in Medicare Beneficiaries With Dementia, From 2006 to 2012. Gerontology and Geriatric Medicine, 2017, 3, 233372141770494.	1.5	4
61	Outcomes of Patients With Atrial Fibrillation Newly Recommended for Oral Anticoagulation Under the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society Guideline. Journal of the American Heart Association, 2018, 7, .	3.7	4
62	Comparing state, regional, and local variation in concurrent opioid and benzodiazepine use. Drug and Alcohol Dependence, 2018, 191, 141-144.	3.2	4
63	Comparison of Oral Anticoagulant Use and Stroke Risk Among Older Adults Newly-Diagnosed Atrial Fibrillation Living in Urban-Versus-Rural Areas. American Journal of Cardiology, 2020, 130, 64-69.	1.6	4
64	Trends in List and Net Prices of Self-administered Systemic Psoriasis Therapies Manufactured by US-Based Pharmaceutical Companies. JAMA Dermatology, 2020, 156, 1136.	4.1	4
65	Association between opioid dose escalation and time to death in a comfort measures only population. American Journal of Health-System Pharmacy, 2021, 78, 203-209.	1.0	4
66	Pricing of Monoclonal Antibodies in the United States. Global Journal on Quality and Safety in Healthcare, 2018, 1, 4-5.	0.5	4
67	Association of formulary restrictions and initiation of an SGLT2i or GLP1-RA among Medicare beneficiaries with type 2 diabetes. Diabetes Research and Clinical Practice, 2022, 187, 109855.	2.8	4
68	Lowering the <i>P</i> Value Threshold. JAMA - Journal of the American Medical Association, 2018, 320, 935.	7.4	3
69	Number of manufacturers and generic drug pricing from 2005 to 2017. American Journal of Managed Care, 2019, 25, 348-352.	1.1	3
70	Identifying Patients at Risk of Acute Kidney Injury Among Medicare Beneficiaries With Type 2 Diabetes Initiating SGLT2 Inhibitors: A Machine Learning Approach. Frontiers in Pharmacology, 2022, 13, 834743.	3.5	3
71	Consequences of forgoing prescription drug subsidies among <scp>lowâ€income</scp> Medicare beneficiaries with diabetes. Health Services Research, 2022, 57, 1136-1144.	2.0	3
72	Avoiding rash decisions about zoster vaccination: insights from cost-effectiveness evidence. BMC Medicine, 2018, 16, 238.	5.5	2

#	Article	IF	CITATIONS
73	Statins for Primary Prevention of Cardiovascular Disease. Annals of Internal Medicine, 2019, 171, 72.	3.9	2
74	Impact of direct-to-consumer drug advertising during the Super Bowl on drug utilization. Research in Social and Administrative Pharmacy, 2020, 16, 1136-1139.	3.0	2
75	Trends in list prices, net prices, and discounts of self-administered injectable tumor necrosis factor inhibitors. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 112-117.	0.9	2
76	Impact of the COVID-19 Pandemic on Global Anticoagulant Sales: A Cross-Sectional Analysis Across 39 Countries. American Journal of Cardiovascular Drugs, 2021, 21, 581-583.	2.2	2
77	A decade of increases in Medicare Part B pharmaceutical spending: what are the drivers?. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 565-573.	0.9	2
78	Trends in the Use of Conventional and New Pharmaceuticals for Hemophilia Treatments Among Medicaid Enrollees, 2005-2020. JAMA Network Open, 2021, 4, e2112044.	5.9	2
79	Relationships between provider-led health plans and quality, utilization, and satisfaction. American Journal of Managed Care, 2018, 24, 628-632.	1.1	2
80	Drug Shortages and Group Purchasing Organizations—Reply. JAMA - Journal of the American Medical Association, 2020, 324, 809.	7.4	1
81	Estimating Discounts for Top Spending Drugs in Medicare Part D. Journal of General Internal Medicine, 2020, 36, 2503-2505.	2.6	1
82	Risk Factors for Cardiovascular Events in Patients on Antidementia Medications. American Journal of Alzheimer's Disease and Other Dementias, 2020, 35, 153331752092238.	1.9	1
83	Joint Latent Class Analysis of Oral Anticoagulation Use and Risk of Stroke or Systemic Thromboembolism in Patients with Atrial Fibrillation. American Journal of Cardiovascular Drugs, 2021, 21, 573-580.	2.2	1
84	The Costs of Delayed Generic Drug Entry: Evidence from a Controversial Prostate Cancer Drug Patent. Journal of General Internal Medicine, 2021, , 1.	2.6	1
85	Emerging treatments for lupus nephritis: health equity considerations in clinical research and coverage. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 1500-1502.	0.9	1
86	Racial and Urban-Rural Difference in the Frequency of Ischemic Stroke as Initial Manifestation of Atrial Fibrillation. Frontiers in Public Health, 2021, 9, 780185.	2.7	1
87	Incidence of fracture events with teriparatide: role of study design. Osteoporosis International, 2015, 26, 2219-2219.	3.1	0
88	Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine. JAMA Internal Medicine, 2018, 178, 873.	5.1	0
89	Savings from the EpiPen Authorized Generic: a Retrospective Analysis of Medicaid Data. Journal of General Internal Medicine, 2019, 34, 1682-1684.	2.6	0
90	Drug Prices, Rebates, and Discounts—Reply. JAMA - Journal of the American Medical Association, 2020, 324, 399.	7.4	0

#	Article	IF	CITATIONS
91	Abstract MP18: Trajectories of Oral Anticoagulation Adherence After First Atrial Fibrillation Diagnosis. Circulation, 2019, 139, .	1.6	Ο
92	Decomposition of Expenditures for Insulins Across the Distribution Chain—Insights Into Rising Prices?. JAMA Health Forum, 2021, 2, e212258.	2.2	0
93	Primary care provider payment models and adherence to anticoagulation in patients with atrial fibrillation. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 1672-1679.	0.9	ο
94	Comparison of oral anticoagulation use and adherence among Medicare beneficiaries enrolled in stand-alone prescription drug plans vs Medicare Advantage prescription drug plans. Journal of Managed Care & Specialty Pharmacy, 2022, 28, 266-274.	0.9	0